HaTinh Pharmaceutical Joint Stock Co
UUPCOM:HDP27,000.00
VND
+200.00
(+0.75%)
HaTinh Pharmaceutical Joint Stock Co
UPCOM:HDP
(Unlisted Public Company Market)
Recent
price
27,000.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ha Tinh Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical company primarily engaged in the research, development, manufacturing, and commercial distribution of modern pharmaceuticals, traditional herbal medicines, dietary supplements, and medical supplies. The company offers a comprehensive portfolio of healthcare products, including prescription and over-the-counter Western pharmaceuticals encompassing antibiotics, analgesics, antipyretics, anti-inflammatory agents, cardiovascular drugs, respiratory treatments, and gastrointestinal medications; traditional herbal medicines and phytotherapeutic remedies, such as herbal cough syrups, digestive tonics, rheumatic formulas, and blood circulation enhancers; nutritional supplements, vitamins, and mineral formulations; medical consumables, antiseptic solutions, and physiological saline; and personal care and cosmeceutical preparations. The company manufactures its formulations across certified World Health Organization Good Manufacturing Practice (WHO-GMP), Good Laboratory Practice (GLP), and Good Storage Practice (GSP) facilities, producing various dosage forms including tablets, capsules, oral liquids, syrups, powders, and topical ointments. Ha Tinh Pharmaceutical Joint Stock Company serves public and private hospitals, clinics, wholesale distributors, and retail pharmacy chains throughout Vietnam, alongside exporting select products to neighboring regional markets including Laos and Cambodia. Founded in 1960 and headquartered in Ha Tinh City, Vietnam, the company has recently undertaken strategic operational enhancements, including upgrading its WHO-GMP production lines, investing in advanced herbal extraction and processing technologies, developing standardized Good Agricultural and Collection Practices (GACP-WHO) medicinal herb cultivation zones, expanding its non-prescription and functional food product offerings, and modernizing its supply chain and distribution partnerships across regional healthcare networks.